BCR-ABL mutations in chronic myeloid leukemia treated with tyrosine kinase inhibitors and impact on survival.
This is the largest Latin American study of BCR-ABL mutations in chronic myeloid leukemia (CML) patients, resistant to imatinib (IM). In 195/467 (41%) patients, mutations were detected. The most frequent mutation was T315I (n = 31, 16%). Progression-free (PFS) and overall survival (OS) at 5 years were lower in patients with BCR-ABL mutations (43% vs. 65%, p = 0.07 and 47% vs. 72%, p = 0.03, respectively) and in those with the T315I mutation (p = 0.003 and p = 0.03). OS and PFS were superior in subgroup who switched to second generation inhibitors (SGIs) after IM failure (OS: 50% vs. 39% p = 0.01; PFS: 48% vs. 30% p = 0.02). BCR-ABL mutations conferred a significant poor prognosis in CML patients.
['Pagnano|Katia Borgia Barbosa|KB|', 'Bendit|Israel|I|', 'Boquimpani|Carla|C|', 'De Souza|Carmino Antonio|CA|', 'Miranda|Eliana C M|EC|', 'Zalcberg|Ilana|I|', 'Larripa|Irene|I|', 'Nardinelli|Luciana|L|', 'Silveira|Rosana Antunes|RA|', 'Fogliatto|Laura|L|', 'Spector|Nelson|N|', 'Funke|Vaneuza|V|', 'Pasquini|Ricardo|R|', 'Hungria|Vania|V|', 'Chiattone|Carlos Sérgio|CS|', 'Clementino|Nelma|N|', 'Conchon|Monika|M|', 'Moiraghi|Elena Beatriz|EB|', 'Lopez|Jose Luis|JL|', 'Pavlovsky|Carolina|C|', 'Pavlovsky|Miguel A|MA|', 'Cervera|Eduardo E|EE|', 'Meillon|Luis Antonio|LA|', 'Simões|Belinda|B|', 'Hamerschlak|Nelson|N|', 'Bozzano|Alicia Helena Magarinos|AH|', 'Mayta|Ernesto|E|', 'Cortes|Jorge|J|', 'Bengió|Raquel M|RM|', '|||']
D000293:Adolescent D000328:Adult D000368:Aged D000369:Aged, 80 and over D000970:Antineoplastic Agents D002648:Child D002675:Child, Preschool D018572:Disease-Free Survival D005260:Female D016313:Genes, abl D006801:Humans D000068877:Imatinib Mesylate D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive D008297:Male D008875:Middle Aged D009154:Mutation D011379:Prognosis D047428:Protein Kinase Inhibitors D011505:Protein-Tyrosine Kinases D012189:Retrospective Studies D055815:Young Adult
BCR-ABL mutations Chronic myeloid leukemia Tyrosine kinase inhibitors Resistance Imatinib